Why the study?
Can monoclonal antibodies Mab1 and Mab2 be used to quantify total and ligand-occupied GPIIb/IIIa receptors during administration of a GPIIb/IIIa antagonist?
Population
Purified GPIIb/IIIa receptors, platelets in vitro, and patients undergoing coronary angioplasty
Comparison
Monoclonal antibodies LYP18 and 4F8 for receptor… vs Matching placebo (for the patient cohort)
Design
Other
Follow-up
6 hours after dosing
Authors
Loading...
Mab2 binding tracks GPIIb/IIIa occupancy during xemilofiban; leaves open whether this assay improves monitoring or outcomes.
Can monoclonal antibodies Mab1 and Mab2 be used to quantify total and ligand-occupied GPIIb/IIIa receptors during administration of a GPIIb/IIIa antagonist?
Monoclonal antibodies Mab1 and Mab2 can differentially quantify total and ligand-occupied GPIIb/IIIa receptors, providing a method to monitor receptor occupancy during antagonist therapy.
Quinn et al. (1999) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: